Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
Go back to Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma| Merck & Co. (NYSE: MRK) | Delayed: 118.94 +3.46 (3.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $119.03 | P/E | 80.91 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 3,717,592 | |||||
